← Leaderboards
Jose A Halperin
Harvard University (Medical School)
$24,126,775
Attributed
$24,126,775
Total exposure
12
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.9M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$24,126,775 · 12
By mechanism
R01$18,322,685 · 9
U19$5,089,927 · 1
R21$459,928 · 1
R56$254,235 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Complement”
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$128,874,888
- Wafaa M. El-Sadr · Columbia University Health Sciences$101,800,876
- Myron S Cohen · Family Health International$101,800,876
- Steve Riordan · Westat, Inc.$94,143,268
- David R. Weir · University Of Michigan At Ann Arbor$93,718,087
- Stuart L Schreiber · Harvard University (Medical School)$88,512,978
Research focus
ComplementGlycationDiabetes MellitusHyperglycemiaLinkPublishingGenetic Regulatory ProteinPathogenesisComplement SystemGlucoseComplications Of Diabetes MellitusLaboratoriesMolecularAffectDiagnosisEnzyme-Linked Immunosorbent AssayCohortPlasmaPublic Health PrioritiesUnited States National Institutes Of HealthInsulinGlycosylated Hemoglobin AMonoclonal AntibodiesClinical Research
Grant awards (44)
Urine levels of Glycated CD59 for screening and diagnosis of pregnancy-induced glucose intolerance$647,442
R01 · FY2025 · DK · contact PI
Urine levels of Glycated CD59 for screening and diagnosis of pregnancy-induced glucose intolerance$734,290
R01 · FY2024 · DK · contact PI
Blood Levels of Glycated CD59, a Novel Biomarker to Assess Pregnancy-induced Glucose Intolerance$697,796
R01 · FY2023 · DK · contact PI
Blood Levels of Glycated CD59, a Novel Biomarker to Assess Pregnancy-induced Glucose Intolerance$697,796
R01 · FY2022 · DK · contact PI
Blood Levels of Glycated CD59, a Novel Biomarker to Assess Pregnancy-induced Glucose Intolerance$697,796
R01 · FY2021 · DK · contact PI
Blood Levels of Glycated CD59, a Novel Biomarker to Assess Pregnancy-induced Glucose Intolerance$697,796
R01 · FY2020 · DK · contact PI
Blood Levels of Glycated CD59, a Novel Biomarker to Assess Pregnancy-induced Glucose Intolerance$692,866
R01 · FY2019 · DK · contact PI
Human Studies on Blood Levels of Glycated CD59 as a Biomarker in Diabetes$689,030
R01 · FY2018 · DK · contact PI
Human Studies on Blood Levels of Glycated CD59 as a Biomarker in Diabetes$42,000
R01 · FY2018 · DK · contact PI
Human Studies on Blood Levels of Glycated CD59 as a Biomarker in Diabetes$694,341
R01 · FY2017 · DK · contact PI
Human Studies on Blood Levels of Glycated CD59 as a Biomarker in Diabetes$675,664
R01 · FY2016 · DK · contact PI
Human Studies on Blood Levels of Glycated CD59 as a Biomarker in Diabetes$675,381
R01 · FY2015 · DK · contact PI
Glycation inactivation of human CD59 and diabetic complications$410,105
R01 · FY2015 · HL · contact PI
Human Studies on Blood Levels of Glycated CD59 as a Biomarker in Diabetes$709,715
R01 · FY2014 · DK · contact PI
Glycation inactivation of human CD59 and diabetic complications$407,257
R01 · FY2014 · HL · contact PI
Glycation inactivation of human CD59 and diabetic complications$391,792
R01 · FY2013 · HL · contact PI
Glycated CD59 as a novel biomarker of gestational diabetes mellitus$203,953
R21 · FY2013 · DK · contact PI
Glycation inactivation of human CD59 and diabetic complications$288,371
R01 · FY2012 · HL · contact PI
Glycated CD59 as a novel biomarker of gestational diabetes mellitus$255,975
R21 · FY2012 · DK · contact PI
Glycation inactivation of human CD59 and diabetic complications$134,129
R01 · FY2012 · HL · contact PI
Glycated CD59 as a Biomarker for Diabetes$254,235
R56 · FY2010 · DK · contact PI
Prostate Cancer Prevention by n-3 Unsaturated Fatty Acids$536,186
R01 · FY2008 · CA · contact PI
Prostate Cancer Prevention by n-3 Unsaturated Fatty Acids$531,601
R01 · FY2007 · CA · contact PI
Prostate Cancer Prevention by n-3 Unsaturated Fatty Acids$532,290
R01 · FY2006 · CA · contact PI
Complement in the Vascular Complications of Diabetes$728,337
R01 · FY2005 · DK
Prostate Cancer Prevention by n-3 Unsaturated Fatty Acids$530,000
R01 · FY2005 · CA
Inhibition of Translation Initiation in Cancer Therapy$319,412
R01 · FY2005 · CA
Role of Complement in Vascular Diabetic Complications$318,564
R01 · FY2005 · DK
NEW TRANSLATION INITIATION INHIBITORS FOR CANCER THERAPY$1,135,467
U19 · FY2004 · CA
Complement in the Vascular Complications of Diabetes$710,837
R01 · FY2004 · DK
Inhibition of Translation Initiation in Cancer Therapy$319,412
R01 · FY2004 · CA
Role of Complement in Vascular Diabetic Complications$318,564
R01 · FY2004 · DK
NEW TRANSLATION INITIATION INHIBITORS FOR CANCER THERAPY$1,102,391
U19 · FY2003 · CA
Complement in the Vascular Complications of Diabetes$693,424
R01 · FY2003 · DK
Inhibition of Translation Initiation in Cancer Therapy$319,412
R01 · FY2003 · CA
Role of Complement in Vascular Diabetic Complications$318,564
R01 · FY2003 · DK
NEW TRANSLATION INITIATION INHIBITORS FOR CANCER THERAPY$1,071,656
U19 · FY2002 · CA
Complement in the Vascular Complications of Diabetes$697,674
R01 · FY2002 · DK
Role of Complement in Vascular Diabetic Complications$403,513
R01 · FY2002 · DK
Inhibition of Translation Initiation in Cancer Therapy$319,412
R01 · FY2002 · CA
NEW TRANSLATION INITIATION INHIBITORS FOR CANCER THERAPY$1,047,084
U19 · FY2001 · CA
NEW TRANSLATION INITIATION INHIBITORS FOR CANCER THERAPY$733,329
U19 · FY2000 · CA
COMPLEMENT AND THE COMPLICATIONS OF DIABETES$472,374
R01 · FY2000 · DK
INHIBITION OF TRANSLATION INITIATION IN CANCER THERAPY$269,542
R01 · FY2000 · CA